Ovarian Cancer Trial, Not Yet Recruiting NCT06726330 Sponsor: Centre Oscar Lambret Condition: Ovarian Cancer
Back to Ovarian Cancer

Ovarian Cancer Trial, Not Yet Recruiting

NCT06726330
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • Women between 35 and 50 years of age.
  • Women who are attending or being followed up in a genetic counselling service related to cancer risk.
  • Women who have been identified as having a higher risk of ovarian, fallopian tube, or peritoneal cancer based on specific gene mutations (BRCA1, BRCA2, RAD51C, RAD51D, or PALB2 — the list of mutations considered may be expanded during the study).
  • Women who have given written agreement to take part in the trial.
  • Women covered by the French Social Security health system.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • Women who have previously had both ovaries removed and/or both fallopian tubes removed, for any reason.
  • Women with a personal history of ovarian, fallopian tube, or peritoneal cancer.
  • Women who have reached menopause — how this is determined depends on individual circumstances, including whether they have had chemotherapy or a hysterectomy, or have a progesterone-releasing intrauterine device (confirm with trial site).
  • Women who would be unable to attend regular follow-up appointments for the trial due to geographical, social, or psychological reasons.
  • Women who are under legal guardianship or curatorship.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Carlos MARTINEZ GOMEZ, MD, Centre Oscar Lambret

Phone: 0320295918

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
Centre Oscar Lambret
Registry
ClinicalTrials.gov
Start date
1 March 2027
Est. completion
1 March 2071

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Incidence of Advanced-Stage (Stage III or IV) Tubo-Ovarian or Primary Peritoneal Carcinoma

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov